US equities |
MU $904.90 ▲+0.00% SNDK $1,371.12 ▲+0.00% NVDA $217.09 ▲+0.00% SKHY $142.87 ▲+0.00% TSLA $368.06 ▲+0.00% SPCX $147.96 ▲+0.00% AAPL $342.94 ▲+0.00% INTC $92.03 ▲+0.00%
FinancialContent

Articles published by Acorda Therapeutics

News headline image
Acorda Therapeutics Announces Delisting from Nasdaq
From Acorda Therapeutics
Via Business Wire
Tickers ACOR ACORQ OTC
News headline image
Acorda Therapeutics Announces Nasdaq Delisting Notification
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Tom Burns Elected to the Acorda Therapeutics Board of Directors
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics Reports First Quarter 2023 Financial Results
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Launches INBRIJA® TV Commercial for Parkinson’s Awareness Month
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
ESTEVE Launches INBRIJA® in Spain
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics to Present at Sequire Biotechnology Conference
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
From Acorda Therapeutics
Via Business Wire
Tickers ACOR
News headline image
Acorda Therapeutics Announces Revised Long-Term Financial Guidance
From Acorda Therapeutics
Via Business Wire
Tickers ACOR